Research programme: Parkinson's disease cell therapies - Buck Institute/Q Therapeutics
Latest Information Update: 04 Nov 2017
At a glance
- Originator Buck Institute for Age Research; Q Therapeutics
- Developer Buck Institute for Research on Aging; Q Therapeutics
- Class Cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Dopaminergic cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Parkinson's-disease in USA (Parenteral)
- 03 Dec 2012 patent info 9144159
- 17 Apr 2008 Early research in Parkinson's disease in USA (Parenteral)